Stockscreener 앱 받기
45.00
4.87%
2.09
시간 외 거래:
45.50
0.50
+1.11%
Structure Therapeutics Inc Adr 주식(GPCR)의 최신 뉴스
(GPCR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock? - TradingView
Why Structure Therapeutics’ Hot Obesity Stock Is Suddenly Sinking - TipRanks
H.C. Wainwright cuts Structure Therapeutics stock price target to $70 By Investing.com - Investing.com Canada
Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs? - TradingView
Why Structure Therapeutics Shares Are Suddenly Sinking - TipRanks
Structure Therapeutics Maintained at Buy as Analyst Highlights Best-in-Class Oral GLP-1 Profile and Keeps $145 Price Target Unchanged - TipRanks
Why Structure Therapeutics Stock Is Sliding Today - TipRanks
Zevra Therapeutics (NASDAQ: ZVRA) vote keeps classified board structure - Stock Titan
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity - The Manila Times
Oral obesity drug helped people lose up to 16% body weight in trial - Stock Titan
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s? - TradingView
LLY Rises 14% in a Month: Should You Hold as Obesity Growth Continues? - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why Structure Therapeutics Stock Is Surging Higher - TipRanks
Structure Therapeutics IncADR (GPCR) News, Articles, Events & Latest Updates - Stocktwits
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), AngioDynamics (ANGO) - The Globe and Mail
LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst? - TradingView
Analysts Offer Insights on Healthcare Companies: Agilent (A), Apogee Therapeutics (APGE) and Pfizer (PFE) - The Globe and Mail
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million - AOL.com
Hear Structure Therapeutics at Jefferies and Goldman Sachs healthcare talks - Stock Titan
Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth? - TradingView
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position - AOL.com
Why (GPCR) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Why Structure Therapeutics Shares Are Sinking Today - TipRanks
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and Protara Therapeutics (TARA) - The Globe and Mail
Monashee Reduces Stake in Structure Therapeutics Amid Competitive Landscape - Intellectia AI
Monashee Scales Back Its Bet on Structure Therapeutics - Yahoo Finance
HighVista Strategies Sells 69,092 Shares of Structure Therapeutics in Q1 2026News and Statistics - IndexBox
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million - The Globe and Mail
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million - The Motley Fool
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Journey Medical Corp (DERM) - The Globe and Mail
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure? - TradingView
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR) - The Globe and Mail
Understanding Momentum Shifts in (GPCR) - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Siemens Healthineers AG (OtherSEMHF) and BioNTech SE (BNTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Cantor Fitzgerald - The Globe and Mail
NVO Rallies 21% in a Month: How Should Investors Play the Stock? - TradingView
Brokers Offer Predictions for GPCR Q1 Earnings - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Announces Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
GPCR Structure posts massive EPS miss as losses widen; stock barely flinches, down 0.13%.Product Revenue - Newser
Structure Therapeutics ADA Data Could Reframe Oral Obesity And Diabetes Prospects - Sahm
Structure Therapeutics Reports 16% Weight Loss With Oral GLP-1RA Aleniglipron in Phase 2, Prepares for Phase 3 Obesity Trial and ADA 2026 Data Presentations - Minichart
Analysts’ Top Healthcare Picks: Addus Homecare (ADUS), Aardvark Therapeutics, Inc. (AARD) - The Globe and Mail
Structure Therapeutics Expands ATM Capacity, Advances Obesity Program - TipRanks
Structure Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Structure Therapeutics (NASDAQ: GPCR) funds obesity drug push with $1.46B cash - Stock Titan
Obesity drug gains momentum as Structure (NASDAQ: GPCR) eyes Phase 3, boosts ATM - Stock Titan
Obesity pill developer posts 16.3% weight loss, targets Phase 3 - Stock Titan
GPCR (NASDAQ: GPCR) expands ATM program to $400M capacity - Stock Titan
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), OnKure Therapeutics (OKUR) and Cogent Biosciences (COGT) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Evolus (EOLS) - The Globe and Mail
LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits? - TradingView
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Alignment Healthcare (ALHC) - The Globe and Mail
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock? - TradingView
Structure Therapeutics (GPCR) Is Down 7.2% After Strong Phase 2 Oral GLP‑1 Obesity Data – Has The Bull Case Changed? - Sahm
2.60%
0.94%
자본화:
|
볼륨(24시간):